Phase 3 Endometriosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older
- People who are planning to have a scheduled (non-emergency) keyhole or robotic surgery for known or suspected endometriosis
Who may not be able to join:
- People who have a high risk of blood clots in arteries or veins
- People who are pregnant
- People who have been diagnosed with osteoporosis
- People who currently have, or have previously had, breast cancer or other cancers that are affected by hormones
- People who have liver damage or liver disease
- People who have unexplained unusual bleeding from the uterus that has not been diagnosed
- People who are allergic to any ingredients in the study medication (called REL-CT)
- People who have not stopped using certain hormonal medications within the required timeframes — specifically: skin patches, oral pills, or vaginal rings must be stopped the day before surgery; hormonal IUDs or implants must be removed during surgery; injectable hormonal medications must have been stopped at least 12 weeks before surgery
- People whose primary spoken language is not English or Spanish
- People who wish to become pregnant within 6 months after their surgery
- People whose pre-surgery pregnancy test comes back positive (confirm with trial site)
- People whose surgery does not find confirmed tissue evidence of endometriosis will be removed from the study before receiving the study treatment
- People whose surgery becomes more extensive than planned — for example, requiring open abdominal surgery rather than keyhole surgery — will be removed from the study before receiving the study treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jordan Klebanoff, MD, Main Line Health
Phone: 610-896-4380
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
This study aims to determine if immediate postoperative medical suppression with Regugolix combination therapy (Rel-CT) following excisional surgery for endometriosis is superior to surgery alone.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.